Insulet Corporation

This study tested a next-generation automated insulin delivery system in 48 adults with type 2 diabetes aged 16–70. The goal was to see if the smart algorithm could keep blood sugar in a safer range, reducing both low and high blood sugar events. Participants used a continuous gl…

This study tested a wearable insulin pump system (Omnipod M) in 40 adults aged 18-75 with type 2 diabetes. The goal was to see if the system helps keep blood sugar in a safe range and reduces dangerous highs and lows. Participants used the system for 6 weeks, and researchers meas…

This study tested whether the Omnipod 5, a tubeless automated insulin pump, works better than multiple daily insulin injections for managing type 1 diabetes. 189 children and adults participated. The main goal was to see if the pump improved blood sugar control (HbA1c) over 13 we…

This study tested whether a simplified approach to starting automated insulin delivery works safely in adults with type 2 diabetes. 56 participants used the Omnipod M System with a continuous glucose monitor, starting with either a lower or higher insulin dose. The goal was to se…

This study tested the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 system, an automated insulin pump, in 48 people aged 2 to 70 with type 1 or type 2 diabetes. The system uses a continuous glucose monitor to automatically adjust insulin delivery. The main goals were …

This study compared a new version of the Omnipod insulin pump (SmartAdjust 2.0) to the current Omnipod 5 in 132 people with type 1 or type 2 diabetes, ages 2 to 70. Participants used each system for about a month to see if the new one is safe and helps keep blood sugar in a healt…

This study tested the Omnipod 5, a wearable device that automatically delivers insulin, in 343 adults with type 2 diabetes. Participants used the system for 13 weeks to see if it improved blood sugar levels. The goal was to make diabetes management simpler and more effective.

This study tested the Omnipod 5, an automated insulin delivery system, against standard insulin pumps in 196 adults with type 1 diabetes. Participants used their usual therapy for 14 days, then either switched to Omnipod 5 or stayed on their pump for 90 days. The goal was to see …